- New insights on safety, adherence, and patient satisfaction with ESO-101 to be presented on May 3, 2025, at DDW 2025.
- ESO-101 features EsoCap’s proprietary drug delivery technology to enable localized treatment of the esophageal lining with the anti-inflammatory corticosteroid mometasone furoate.
- The ACESO Phase II study underlines the importance of targeted drug delivery to the esophagus, reinforcing the significance of innovative approaches in the treatment of EoE.
EsoCap AG today announced the highly anticipated presentation of data from the ACESO Phase II study at Digestive Disease Week (DDW) 2025, taking place May 3–6 in San Diego, USA. The oral presentation, delivered by Prof. Evan Dellon of the University of North Carolina at Chapel Hill, will highlight key findings on the safety, adherence, and satisfaction associated with EsoCap’s novel drug delivery system for eosinophilic esophagitis (EoE). This presentation is scheduled for May 3, 2025, from 4:00 to 5:30 pm in the session titled “What’s New in Eosinophilic Esophagitis?”
